Abstract 48P
Background
Nav1.5 and nNav1.5 are potent metastatic markers for breast cancer with aggressive phenotype; detected in tumour tissues positive for lymph node metastasis. In vitro, most of the studies involving Nav1.5 and nNav1.5 were evaluated in monolayer cultured cells. Subsequently, since 3D-spheroid culture is now known for its ability to mimic multiple in vivo tumour microenvironment, there is a need to re-evaluate the potential role of Nav1.5 and nNav1.5 in a reliable tumour-accurate model. This study aimed to develop MDA-MB-231-3D-spheroid culture and assess the mRNA gene expression of Nav1.5 and nNav1.5 including several other potent markers for aggressive breast cancer, MMP1, MMP13 and fibronectin.
Methods
MDA-MB-231-3D-spheroids were cultured using scaffold-free liquid overlay method (via agarose layered 96-well flat bottomed plate) for 15 days. The total RNA was conventionally extracted and converted to cDNA. The mRNA expression for Nav1.5 and nNav1.5, MMP1, MMP13 and fibronectin were measured using real-time PCR and the expression were analysed via the 2-ΔΔCt method in which the monolayer culture was used as a normalizing control.
Results
MDA-MB-231-3D-spheroid was successfully developed. mRNA expression of Nav1.5, nNav1.5, MMP1 and fibronectin were significantly higher (p < 0.05) in MDA-MB-231-3D-spheroid compared to the monolayer culture; 4.8-fold, 2.1-fold, 62.1-fold and 5.3-fold, respectively.
Conclusions
Evaluating the role of tumour markers in a reliable tumour-accurate model is very important. MDA-MB-231-3D-spheroid was able to increase the expression of Nav1.5 and nNav1.5 and can be utilized to re-evaluate the role of Nav1.5 and nNav1.5 in cancer metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Research in Molecular Medicine, Universiti Sains Malaysia.
Funding
Universiti Sains Malaysia, FRGS (203/CIPPM/6171212).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract